Sangamo Biosciences (SGMO) 16.53 $SGMO
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Dec 12, 4:39PM CST
ENPH: 12.45 (-0.10), ATTO: 10.51 (-0.39), TVIX: 3.32 (+0.31), GGB: 3.13 (-0.23), ARRS: 27.72 (-0.31), DGAZ: 4.22 (-0.40), SGMO: 16.53 (+2.46), CCXI: 5.60 (+1.11), ILF: 30.63 (-0.90), GSAT: 2.58 (+0.05)
Shares of SGMO Up 16.2% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Dec 12, 9:14AM CST
SmarTrend identified an Uptrend for Sangamo Biosciences (NASDAQ:SGMO) on October 28th, 2014 at $12.13. In approximately 2 month, Sangamo Biosciences has returned 16.16% as of today's recent price of $14.09.
SGMO: 16.53 (+2.46)
Sangamo Biosciences (SGMO) Jumps: Stock Rises 7.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 12, 8:46AM CST
Sangamo Biosciences (SGMO) was a big mover last session, with shares rising over 7%.
BIIB: 344.49 (+2.16), ANIP: 54.28 (+2.33), SGMO: 16.53 (+2.46), AFFX: 8.94 (-0.36)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Dec 11, 11:45AM CST
SD: 1.79 (unch), FRO: 2.25 (+0.62), ABCO: 46.02 (+1.45), ZAZA: 1.46 (-0.13), JMEI: 13.50 (-0.01), SGMO: 16.53 (+2.46), TGTX: 18.25 (+0.74), MEI: 34.66 (-0.99), WLT: 1.80 (-0.21), NSPR: 0.94 (+0.03), VII: 1.44 (unch), CVTI: 27.89 (-0.15), MEIP: 4.20 (unch), ALDR: 25.27 (-1.46), CALA: 29.85 (+6.65), CGG: 8.52 (-0.33), SPP: 1.70 (-0.07), DSCO: 1.33 (-0.01), KPTI: 34.85 (+1.35), HBOS: 25.23 (-0.17)
Alpha- Antitrypsin Deficiency - Pipeline Review, H2 2014
M2 - Wed Dec 10, 5:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/vv3g4v/alpha) has announced the addition of the "Alpha- Antitrypsin Deficiency - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Alpha- Antitrypsin Deficiency, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alpha- Antitrypsin Deficiency and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Alpha- Antitrypsin Deficiency - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Alpha- Antitrypsin Deficiency pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Applied Genetic Technologies Corporation - Arrowhead Research Corporation - Carolus Therapeutics - Cevec Pharmaceuticals - Dicerna Pharmaceuticals - Grifols - iBio - International Stem Cell Corporation - Intrexon Corporation - Kamada - OrphageniX - Polyphor - rEVO Biologics - Sangamo BioSciences For more information visit http://www.researchandmarkets.com/research/vv3g4v/alpha
DRNA: 12.88 (+1.19), ARWR: 5.76 (-0.17), SGMO: 16.53 (+2.46), XON: 27.01 (+0.35), RBIO: ()
Sangamo rides bluebird's wave
Seeking Alpha - at Seeking Alpha - Tue Dec 09, 2:45PM CST
BLUE: 91.28 (+5.16), SGMO: 16.53 (+2.46)
Sangamo BioSciences Presents New Data at American Society of Hematology Meeting Demonstrating Broad Application of ZFN Mediated Genome-Editing Approach to Therapeutics for Hemophilia and Lysosomal Storage Disorders
PR Newswire - Mon Dec 08, 6:00AM CST
Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced the presentation of new preclinical data from its proprietary programs for the treatment of lysosomal storage disorders (LSD) and Shire-partnered hemophilia program. These studies demonstrate the broad applicability of Sangamo's In Vivo Protein Replacement Platform (IVPRP) for the potentially curative treatment of such diseases, and were presented at the 56th Annual Meeting of the American Society of Hematology (ASH) held in San Francisco from December 5 to 9, 2014.
SGMO: 16.53 (+2.46)
Calithera Biosciences hires H. Ward Wolff to board
M2 - Wed Dec 03, 7:06AM CST
Pharmaceutical company Calithera Biosciences (NasdaqGS:CALA) reported on Tuesday the addition of H. Ward Wolff to its board of directors as well as chair of its Audit Committee.
PTLA: 28.27 (-0.27), CALA: 29.85 (+6.65), SGMO: 16.53 (+2.46)
Calithera Biosciences Appoints H. Ward Wolff to Board of Directors
GlobeNewswire - Tue Dec 02, 4:00PM CST
Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, announced today the appointment of H. Ward Wolff to the company's Board of Directors, where he will chair the company's Audit Committee. Mr. Wolff is currently Executive Vice President and Chief Financial Officer of Sangamo BioSciences, Inc.
CALA: 29.85 (+6.65), SGMO: 16.53 (+2.46)
Sangamo BioSciences Presents Study At Society For Neuroscience Meeting Demonstrating In Vivo Reversal Of Huntington's Disease Signs And Symptoms
PR Newswire - Wed Nov 19, 6:00AM CST
Sangamo BioSciences, Inc. (NASDAQ: SGMO) announced that positive preclinical data from its joint program with Shire plc, to develop a novel ZFP Therapeutic® approach to Huntington's disease (HD), will be presented at the 2014 Annual Meeting of the Society for Neuroscience. The data were generated by Sangamo scientists and the CHDI Foundation. Neuroscience 2014, which is the world's largest forum for neuroscientists to present their research, is being held in Washington D.C. from November 15-19, 2014.
SHPG: 213.70 (-0.41), SGMO: 16.53 (+2.46)
Sangamo BioSciences Announces Presentation at the 26th Annual Piper Jaffray Healthcare Conference
GlobeNewswire - Tue Nov 18, 3:02PM CST
Sangamo BioSciences, Inc. (Nasdaq:SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeuticdevelopment programs and an overview of the company's business strategy at 8:00 am ET on Tuesday, December 2, 2014, at the 26th Annual Piper Jaffray Healthcare Conference in New York.
SGMO: 16.53 (+2.46)
Insider Trading Alert - CCOI, CRM And SGMO Traded By Insiders
at The Street - Fri Nov 14, 10:49AM CST
Stocks with insider trader activity include CCOI, CRM and SGMO
CCOI: 33.40 (-0.79), SGMO: 16.53 (+2.46), CRM: 55.07 (-0.41)
Earnings Look Back: Sangamo Biosciences Is Up 9.5% Since Reporting Quarterly Results 2 Weeks Ago (SGMO)
Comtex SmarTrend(R) - Mon Nov 10, 12:49PM CST
19 days ago, on October 22nd, 2014, Sangamo Biosciences (NASDAQ:SGMO) reported its earnings. Analysts, on average, expected a loss of $0.14 per share on sales of $8.5 million. Sangamo Biosciences actually reported a loss of $0.11 per share on sales of $12.4 million, beating EPS estimates by $0.03 and beating revenue estimates by $4.0 million. Shares of Sangamo Biosciences have climbed from $10.34 to $11.32, representing a gain of 9.5% since the company reported earnings 19 days ago.
SGMO: 16.53 (+2.46)
Sangamo BioSciences President and CEO Edward Lanphier to Serve as Chairman of the Alliance for Regenerative Medicine
PR Newswire - Mon Nov 10, 8:05AM CST
Sangamo BioSciences, Inc. (NASDAQ: SGMO) announced that Edward Lanphier, the Company's president and CEO, has been elected to serve as the next Chairman of the Alliance for Regenerative Medicine (ARM). Washington, DC-based ARM is an international organization that represents and supports industry, clinical institutions, patient advocates and other stakeholders in the development of safe and effective gene and cell therapies. Mr. Lanphier succeeds Geoff MacKay, president and CEO of Organogenesis Inc., who will complete his two-year term as chairman on December 31, 2014.
SGMO: 16.53 (+2.46)
The Alliance for Regenerative Medicine Elects Edward Lanphier as Chairman, Welcomes New Officers and Executive Committee Members
GlobeNewswire - Mon Nov 10, 8:04AM CST
via PRWEB - The Alliance for Regenerative Medicine (ARM), the international organization representing the regenerative medicine and advanced therapies community, announces the election of Edward Lanphier, Founder, President and Chief Executive Officer (CEO) of Sangamo BioSciences (NASDAQ: SGMO), as its next Chairman. Robert Preti, Ph.D., Co-founder, President and Chief Scientific Officer (CSO) of Progenitor Cell Therapy (PCT) and CSO of NeoStem, has been named Vice-Chairman. Claudia Zylberberg, Ph.D., CEO of Akron Biotech, was elected as Treasurer and Phil Vanek, Ph.D., General Manager Cell BioProcessing at GE Healthcare, was elected Secretary. Mr. Lanphier will replace Geoff MacKay, President and CEO of Organogenesis Inc., who will complete his two-year term as Chairman on December 31, 2014.
SGMO: 16.53 (+2.46)
Sangamo Biosciences (SGMO) Upgraded From Sell to Hold
at The Street - Thu Oct 30, 8:54AM CDT
Sangamo Biosciences (SGMO) has been upgraded by TheStreet Ratings from Sell to Hold with a ratings score of C-.
SGMO: 16.53 (+2.46)
Sangamo Biosciences' (SGMO) CEO Edward Lanphier on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Oct 22, 10:01PM CDT
SGMO: 16.53 (+2.46)
Sangamo BioSciences revises guidance after Q3 results
Seeking Alpha - at Seeking Alpha - Wed Oct 22, 4:59PM CDT
SGMO: 16.53 (+2.46)
Sangamo BioSciences (SGMO) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Wed Oct 22, 3:55PM CDT
SGMO: 16.53 (+2.46)
Sangamo BioSciences beats by $0.03, beats on revenue
Seeking Alpha - at Seeking Alpha - Wed Oct 22, 3:08PM CDT
SGMO: 16.53 (+2.46)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Dec 12, 4:39PM CST
ENPH: 12.45 (-0.10), ATTO: 10.51 (-0.39), TVIX: 3.32 (+0.31), GGB: 3.13 (-0.23), ARRS: 27.72 (-0.31), DGAZ: 4.22 (-0.40), SGMO: 16.53 (+2.46), CCXI: 5.60 (+1.11), ILF: 30.63 (-0.90), GSAT: 2.58 (+0.05)
Shares of SGMO Up 16.2% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Dec 12, 9:14AM CST
SmarTrend identified an Uptrend for Sangamo Biosciences (NASDAQ:SGMO) on October 28th, 2014 at $12.13. In approximately 2 month, Sangamo Biosciences has returned 16.16% as of today's recent price of $14.09.
SGMO: 16.53 (+2.46)
Sangamo Biosciences (SGMO) Jumps: Stock Rises 7.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 12, 8:46AM CST
Sangamo Biosciences (SGMO) was a big mover last session, with shares rising over 7%.
BIIB: 344.49 (+2.16), ANIP: 54.28 (+2.33), SGMO: 16.53 (+2.46), AFFX: 8.94 (-0.36)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Dec 11, 11:45AM CST
SD: 1.79 (unch), FRO: 2.25 (+0.62), ABCO: 46.02 (+1.45), ZAZA: 1.46 (-0.13), JMEI: 13.50 (-0.01), SGMO: 16.53 (+2.46), TGTX: 18.25 (+0.74), MEI: 34.66 (-0.99), WLT: 1.80 (-0.21), NSPR: 0.94 (+0.03), VII: 1.44 (unch), CVTI: 27.89 (-0.15), MEIP: 4.20 (unch), ALDR: 25.27 (-1.46), CALA: 29.85 (+6.65), CGG: 8.52 (-0.33), SPP: 1.70 (-0.07), DSCO: 1.33 (-0.01), KPTI: 34.85 (+1.35), HBOS: 25.23 (-0.17)
Alpha- Antitrypsin Deficiency - Pipeline Review, H2 2014
M2 - Wed Dec 10, 5:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/vv3g4v/alpha) has announced the addition of the "Alpha- Antitrypsin Deficiency - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Alpha- Antitrypsin Deficiency, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alpha- Antitrypsin Deficiency and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Alpha- Antitrypsin Deficiency - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Alpha- Antitrypsin Deficiency pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Applied Genetic Technologies Corporation - Arrowhead Research Corporation - Carolus Therapeutics - Cevec Pharmaceuticals - Dicerna Pharmaceuticals - Grifols - iBio - International Stem Cell Corporation - Intrexon Corporation - Kamada - OrphageniX - Polyphor - rEVO Biologics - Sangamo BioSciences For more information visit http://www.researchandmarkets.com/research/vv3g4v/alpha
DRNA: 12.88 (+1.19), ARWR: 5.76 (-0.17), SGMO: 16.53 (+2.46), XON: 27.01 (+0.35), RBIO: ()
Sangamo rides bluebird's wave
Seeking Alpha - at Seeking Alpha - Tue Dec 09, 2:45PM CST
BLUE: 91.28 (+5.16), SGMO: 16.53 (+2.46)
Sangamo BioSciences Presents New Data at American Society of Hematology Meeting Demonstrating Broad Application of ZFN Mediated Genome-Editing Approach to Therapeutics for Hemophilia and Lysosomal Storage Disorders
PR Newswire - Mon Dec 08, 6:00AM CST
Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced the presentation of new preclinical data from its proprietary programs for the treatment of lysosomal storage disorders (LSD) and Shire-partnered hemophilia program. These studies demonstrate the broad applicability of Sangamo's In Vivo Protein Replacement Platform (IVPRP) for the potentially curative treatment of such diseases, and were presented at the 56th Annual Meeting of the American Society of Hematology (ASH) held in San Francisco from December 5 to 9, 2014.
SGMO: 16.53 (+2.46)
Calithera Biosciences hires H. Ward Wolff to board
M2 - Wed Dec 03, 7:06AM CST
Pharmaceutical company Calithera Biosciences (NasdaqGS:CALA) reported on Tuesday the addition of H. Ward Wolff to its board of directors as well as chair of its Audit Committee.
PTLA: 28.27 (-0.27), CALA: 29.85 (+6.65), SGMO: 16.53 (+2.46)
Calithera Biosciences Appoints H. Ward Wolff to Board of Directors
GlobeNewswire - Tue Dec 02, 4:00PM CST
Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, announced today the appointment of H. Ward Wolff to the company's Board of Directors, where he will chair the company's Audit Committee. Mr. Wolff is currently Executive Vice President and Chief Financial Officer of Sangamo BioSciences, Inc.
CALA: 29.85 (+6.65), SGMO: 16.53 (+2.46)
Sangamo BioSciences Presents Study At Society For Neuroscience Meeting Demonstrating In Vivo Reversal Of Huntington's Disease Signs And Symptoms
PR Newswire - Wed Nov 19, 6:00AM CST
Sangamo BioSciences, Inc. (NASDAQ: SGMO) announced that positive preclinical data from its joint program with Shire plc, to develop a novel ZFP Therapeutic® approach to Huntington's disease (HD), will be presented at the 2014 Annual Meeting of the Society for Neuroscience. The data were generated by Sangamo scientists and the CHDI Foundation. Neuroscience 2014, which is the world's largest forum for neuroscientists to present their research, is being held in Washington D.C. from November 15-19, 2014.
SHPG: 213.70 (-0.41), SGMO: 16.53 (+2.46)
Sangamo BioSciences Announces Presentation at the 26th Annual Piper Jaffray Healthcare Conference
GlobeNewswire - Tue Nov 18, 3:02PM CST
Sangamo BioSciences, Inc. (Nasdaq:SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeuticdevelopment programs and an overview of the company's business strategy at 8:00 am ET on Tuesday, December 2, 2014, at the 26th Annual Piper Jaffray Healthcare Conference in New York.
SGMO: 16.53 (+2.46)
Insider Trading Alert - CCOI, CRM And SGMO Traded By Insiders
at The Street - Fri Nov 14, 10:49AM CST
Stocks with insider trader activity include CCOI, CRM and SGMO
CCOI: 33.40 (-0.79), SGMO: 16.53 (+2.46), CRM: 55.07 (-0.41)
Earnings Look Back: Sangamo Biosciences Is Up 9.5% Since Reporting Quarterly Results 2 Weeks Ago (SGMO)
Comtex SmarTrend(R) - Mon Nov 10, 12:49PM CST
19 days ago, on October 22nd, 2014, Sangamo Biosciences (NASDAQ:SGMO) reported its earnings. Analysts, on average, expected a loss of $0.14 per share on sales of $8.5 million. Sangamo Biosciences actually reported a loss of $0.11 per share on sales of $12.4 million, beating EPS estimates by $0.03 and beating revenue estimates by $4.0 million. Shares of Sangamo Biosciences have climbed from $10.34 to $11.32, representing a gain of 9.5% since the company reported earnings 19 days ago.
SGMO: 16.53 (+2.46)
Sangamo BioSciences President and CEO Edward Lanphier to Serve as Chairman of the Alliance for Regenerative Medicine
PR Newswire - Mon Nov 10, 8:05AM CST
Sangamo BioSciences, Inc. (NASDAQ: SGMO) announced that Edward Lanphier, the Company's president and CEO, has been elected to serve as the next Chairman of the Alliance for Regenerative Medicine (ARM). Washington, DC-based ARM is an international organization that represents and supports industry, clinical institutions, patient advocates and other stakeholders in the development of safe and effective gene and cell therapies. Mr. Lanphier succeeds Geoff MacKay, president and CEO of Organogenesis Inc., who will complete his two-year term as chairman on December 31, 2014.
SGMO: 16.53 (+2.46)
The Alliance for Regenerative Medicine Elects Edward Lanphier as Chairman, Welcomes New Officers and Executive Committee Members
GlobeNewswire - Mon Nov 10, 8:04AM CST
via PRWEB - The Alliance for Regenerative Medicine (ARM), the international organization representing the regenerative medicine and advanced therapies community, announces the election of Edward Lanphier, Founder, President and Chief Executive Officer (CEO) of Sangamo BioSciences (NASDAQ: SGMO), as its next Chairman. Robert Preti, Ph.D., Co-founder, President and Chief Scientific Officer (CSO) of Progenitor Cell Therapy (PCT) and CSO of NeoStem, has been named Vice-Chairman. Claudia Zylberberg, Ph.D., CEO of Akron Biotech, was elected as Treasurer and Phil Vanek, Ph.D., General Manager Cell BioProcessing at GE Healthcare, was elected Secretary. Mr. Lanphier will replace Geoff MacKay, President and CEO of Organogenesis Inc., who will complete his two-year term as Chairman on December 31, 2014.
SGMO: 16.53 (+2.46)
Sangamo Biosciences (SGMO) Upgraded From Sell to Hold
at The Street - Thu Oct 30, 8:54AM CDT
Sangamo Biosciences (SGMO) has been upgraded by TheStreet Ratings from Sell to Hold with a ratings score of C-.
SGMO: 16.53 (+2.46)
Sangamo Biosciences' (SGMO) CEO Edward Lanphier on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Oct 22, 10:01PM CDT
SGMO: 16.53 (+2.46)
Sangamo BioSciences revises guidance after Q3 results
Seeking Alpha - at Seeking Alpha - Wed Oct 22, 4:59PM CDT
SGMO: 16.53 (+2.46)
Sangamo BioSciences (SGMO) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Wed Oct 22, 3:55PM CDT
SGMO: 16.53 (+2.46)
Sangamo BioSciences beats by $0.03, beats on revenue
Seeking Alpha - at Seeking Alpha - Wed Oct 22, 3:08PM CDT
SGMO: 16.53 (+2.46)
